EGFR and non-small cell lung carcinoma: Thus, in this study, we aimed to assess the prognostic impact of AI eligibility criteria on patients with NSCLC with EGFR mutation and compare the effectiveness of EGFR‐TKI monotherapy in patients with an L858R mutation to that in those with exon 19 deletion in the AI‐eligible population.